Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.43

+3.8%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$159.68M
EPS-1.6700
P/E Ratio-4.45
Earnings Date08/13/2026

uncy

Common Stock

Last Annual Value

22.00K

3-Year CAGR

14%

5-Year CAGR

20%

10-Year CAGR

-4%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Common Stock

UNCY · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
22.00K
-14.3%8.0%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
24.00K
17.0%13.0%-39.9%
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
79.00K
114.5%81.6%54.8%
32.00K
28.7%-20.5%-4.2%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
11.07K
7.7%7.1%-3.4%
IMA logo
ImageneBio Inc
NASDAQ:IMA
11.00K
-38.8%-21.1%N/A
7.00K
11.9%7.0%N/A
0.00
N/AN/AN/A
136.37M
5.1%11.2%277.5%
31.00K
10.5%73.0%N/A
7.00K
20.5%18.5%N/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.43, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.43